Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.2, pp.155-163, 2021 (SCI-Expanded)
- Publication Type: Article / Article
- Volume: 32 Issue: 2
- Publication Date: 2021
- Doi Number: 10.5152/tjg.2020.19569
- Journal Name: TURKISH JOURNAL OF GASTROENTEROLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Page Numbers: pp.155-163
- Keywords: Chronic hepatitis C, sofosbuvir, ledipasvir, sustained virological response, genotype, real-world data, SOFOSBUVIR PLUS RIBAVIRIN, GENOTYPE 1 INFECTION, TREATMENT-NAIVE, ANTIVIRAL THERAPY, HCV INFECTION, OPEN-LABEL, LEDIPASVIR, SAFETY, LEDIPASVIR/SOFOSBUVIR
- Akdeniz University Affiliated: Yes
Abstract
Background: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice.